Osteocalcin: An endocrine link between bone and glucose metabolism

Expert Review of Endocrinology and Metabolism

Volumn 6, Issue 2, 2011, Pages 177-185

  Yeap, Bu B ^a,b  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b FREMANTLE HOSPITAL   (Australia)

Author keywords

cardiovascular disease; diabetes mellitus; insulin resistance; metabolic syndrome; osteocalcin; undercarboxylated osteocalcin

Indexed keywords

ADIPONECTIN; GLUCOSE; INSULIN; INSULIN RECEPTOR; OSTEOCALCIN;

ADIPOCYTE; BONE METABOLISM; CARBOXYLATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIABETES MELLITUS; DISORDERS OF CARBOHYDRATE METABOLISM; GENE DELETION; GLUCOSE METABOLISM; HUMAN; INSULIN RELEASE; INSULIN RESISTANCE; INSULIN SENSITIVITY; METABOLIC REGULATION; METABOLIC SYNDROME X; NONHUMAN; OSTEOBLAST; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RISK FACTOR;

EID: 79952731095     PISSN: 17446651     EISSN: None     Source Type: Journal    
DOI: 10.1586/eem.11.7     Document Type: Review

References (55)

1. Dunstan D, Zimmet P, Welborn T et al. Diabesity and associated disorders in Australia - 2000: the accelerating epidemic. The Australian Diabetes, Obesity and Lifestyle Study (AusDiab). International Diabetes Institute, Melbourne, Australia (2001).
2. Sorkin JD, Muller DC, Fleg JL, Andres R. The relation of fasting and 2-h postchallenge plasma glucose concentrations to mortality. Diabetes Care 28, 2626-2632 (2005).
3. Rijkelijkhuizen JM, Nijpels G, Heine RJ et al. High risk of cardiovascular mortality in individuals with impaired fasting glucose is explained by conversion to diabetes. Diabetes Care 30, 332-336 (2007).
4. Khaw KT, Wareham N, Luben R et al. Glycated haemoglobin, diabetes, and mortality in men in Norfolk cohort of European Prospective Investigation of Cancer and Nutrition (EPIC-Norfolk). Br. Med. J. 322, 1-6 (2001).
5. Bonora E, Kiechl S, Willeit J et al. Insulin resistance as estimated by homeostasis model assessment predicts incident symptomatic cardiovascular disease in Caucasian subjects from the general population. Diabetes Care 30, 318-324 (2007).
6. Saely CH, Aczel S, Marte T et al. The metabolic syndrome, insulin resistance, and cardiovascular risk in diabetic and nondiabetic patients. J. Clin. Endocrinol. Metab. 90, 5698-5703 (2005).
7. DeFronzo RA. Is insulin resistance atherogenic? Possible mechanisms. Atheroscler. Suppl. 7, 11-15 (2006).
8. Punthakee Z, Werstuck GH, Gerstein HC. Diabetes and cardiovascular disease: explaining the relationship. Rev. Cardiovasc. Med. 8, 145-153 (2007).
9. Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in Type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial. Lancet 364, 685-696 (2004).
10. Holman RR, Paul SK, Bethel MA et al. 10-year follow-up of intensive glucose control in Type 2 diabetes. N. Engl. J. Med. 359, 1577-1589 (2008).
11. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in Type 2 diabetes. N. Engl. J. Med. 358, 580-591 (2008).
12. The Diabetes Prevention Program Research Group. Reduction in the incidence of Type 2 diabetes with lifestyle intervention or metformin. N. Engl. J. Med. 346, 393-403 (2002).
13. Gerstein HC, Yusuf S, Bosch J et al. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial. Lancet 368, 1096-1105 (2006).
14. The Shifting Burden of Cardiovascular Disease in Australia. Report by Access Economics for the Heart Foundation of Australia. Access Economics, Canberra, Australia (2005).
15. Australian Institute of Health and Welfare. Diabetes: Australian Facts 2008. Diabetes series no. 8. Cat. No. CVD40. Australian Institute of Health and Welfare, Canberra, Australia (2008).
16. Kahn SE, Zraika S, Utzschneider KM, Hull RL. The b cell lesion in Type 2 diabetes: there has to be a primary functional abnormality. Diabetologia 52, 1003-1012 (2009).
17. Lee NK, Sowa H, Hinoi E et al. Endocrine regulation of energy metabolism by the skeleton. Cell 130, 456-469 (2007). Important article from the Karsenty laboratory demonstrating a role for undercarboxylated osteocalcin to regulate insulin secretion and sensitivity in mice.
18. Lee NK, Karsenty G. Reciprocal regulation of bone and energy metabolism. Trends Endocrinol. Metab. 19, 161-166 (2008).
19. Hauschka PV, Lian JB, Cole DE, Gundberg CM. Osteocalcin and matrix Gla protein: vitamin K-dependent proteins in bone. Physiol. Rev. 69, 990-1047 (1989).
20. Gundberg CM, Nieman SD, Abrams S, Rosen H. Vitamin K status and bone health: an ana lysis of methods for determination of undercarboxylated osteocalcin. J. Clin. Endocrinol. Metab. 83, 3258-3266 (1998).
21. Ferron M, Hinoi E, Karsenty G, Ducy P. Osteocalcin differentially regulates b cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc. Natl Acad. Sci. USA 105, 5266-5270 (2008). Additional data from the Karsenty laboratory confirming that undercarboxylated osteocalcin is the biologically active form.
22. Rosen CJ. Bone remodelling, energy metabolism, and the molecular clock. Cell Metab. 7, 7-10 (2008).
23. Im J-A, Yu B-P, Jeon JY, Kim S-H. Relationship between osteocalcin and glucose metabolism. Clin. Chim. Acta 396, 66-69 (2008).
24. Zhou M, Ma X, Li H et al. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. Eur. J. Endocrinol. 161, 723-729 (2009).
25. Kindblom JM, Ohlsson C, Ljunggren O et al. Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J. Bone Mineral Res. 24, 785-791 (2009). Large cohort study demonstrating inverse associations of total osteocalcin level with BMI, fat mass and diabetes.
26. Kanazawa I, Yamaguchi T, Yamamoto M et al. Serum osteocalcin level is associated with glucose metabolism and atherosclerosis parameters in Type 2 diabetes. J. Clin. Endocrinol. Metab. 94, 45-49 (2009).
27. Fernandez-Real JM, Izquierdo M, Ortega F et al. The relationship of serum osteocalcin to insulin secretion, sensitivity and disposal with hypocaloric diet and resistance training. J. Clin. Endocrinol. Metab. 94, 237-245 (2009).
28. Pittas AG, Harris SS, Eliades M et al. Association between serum osteocalcin and markers of metabolic phenotype. J. Clin. Endocrinol. Metab. 94, 827-832 (2009). Longitudinal study demonstrating association of higher total osteocalcin level with lower increases in fasting glucose over 3 years.
29. Saleem U, Mosley TH, Kullo IJ. Serum osteocalcin is associated with measures of insulin resistance, adipokine levels, and the presence of metabolic syndrome. Arterioscler. Thromb. Vasc. Biol. 30, 1474-1478 (2010). Large cohort study demonstrating reduced odds of metabolic syndrome in men and women with higher total osteocalcin levels.
30. Yeap BB, Chubb SAP, Flicker L et al. Reduced serum total osteocalcin is associated with metabolic syndrome in older men via waist circumference, hyperglycemia and triglyceride levels. Eur. J. Endocrinol. 163, 265-272 (2010). Large cohort study demonstrating older men with higher total osteocalcin levels had reduced odds of metabolic syndrome. This association was mediated via waist circumference, hyperglycemia and triglyceride levels.
31. Hwang Y-C, Jeong I-K, Ahn KJ, Chung HY. The uncarboxylated form of osteocalcin is associated with improved glucose tolerance and enhanced β-cell function in middle-aged male subjects. Diabetes Metab. Res. Rev. 25, 768-772 (2009). Study demonstrating association of undercarboxylated osteocalcin with insulin sensitivity in men.
32. Shea MK, Gundberg CM, Meigs JB et al. γ-carboxylation of osteocalcin and insulin resistance in older men and women. Am. J. Clin. Nutr. 90, 1230-1235 (2009). Study demonstrating lower total and carboxylated osteocalcin levels were associated with insulin resistance in nondiabetic men and women.
33. Kanazawa I, Yamaguchi T, Yamauchi M et al. Adiponectin is associated with changes in bone markers during glycemic control in Type 2 diabetes mellitus. J. Clin. Endocrinol. Metab. 94, 3031-3037 (2009).
34. Kanazawa I, Yamaguchi T, Yamauchi M et al. Serum undercarboxylated osteocalcin was inversely associated with plasma glucose level and fat mass in Type 2 diabetes mellitus. Osteoporos. Int. 22(1), 187-194 (2011).
35. Takahashi M, Kushida K, Nagano A, Inoue T. Comparison of the analytical and clinical performance characteristics of an N-MID versus an intact osteocalcin immunoradiometric assay. Clin. Chim. Acta 294, 67-76 (2000).
36. Ferron M, Wei J, Yoshizawa T, Ducy P, Karsenty G. An ELISA-based method to quantify osteocalcin carboxylation in mice. Biochem. Biophys. Res. Commun. 397, 691-696 (2010). Study from the Karsenty laboratory investigating new antibodies for detection of murine undercarboxylated osteocalcin.
37. Hylek EM. Oral anticoagulant therapy for patients with atrial fibrillation - an update. Thromb. Res. 123(Suppl. 1), S46-S49 (2010).
38. Medi C, Hankey GJ, Freedman SB. Stroke risk and antithrombotic strategies in atrial fibrillation. Stroke 41, 2705-2713 (2010).
39. Scheen AJ. Drug interactions of clinical importance with antihyperglycaemic agents. An update. Drug Saf. 28, 601-631 (2005).
40. Nimptsch K, Hailer S, Rohrmann S, Gedrich K, Wolfram G, Linseisen J. Determinants and correlates of serum undercarbocylated osteocalcin. Ann. Nutr. Metab. 51, 563-570 (2007).
41. Shea MK, Booth SL, Massaro JM et al. Vitamin K and vitamin D status: associations with inflammatory markers in the Framingham Offspring Study. Am. J. Epidemiol. 167, 313-320 (2008).
42. Cheung AM, Tile L, Lee Y et al. Vitamin K supplementation in postmenopausal women with osteopenia (ECKO trial): a randomised controlled trial. PLOS Med. 5, 1461-1472 (2008).
43. Pearson DA. Bone health and osteoporosis: the role of vitamin K and potential antagonism by anticoagulants. Nutr. Clin. Pract. 22, 517-544 (2007).
44. Yoshida M, Booth SL, Meigs JB, Saltzman E, Jacques PF. Phylloquinone intake, insulin sensitivity, and glycemic status in men and women. Am. J. Clin. Nutr. 88, 210-215 (2008).
45. Pan Y, Jackson RT. Dietary phylloquinone intakes and metabolic syndrome in US young adults. J. Am. Coll. Nutr. 28, 369-379 (2009).
46. Beulens JWJ, van der A DL, Grobbee DE, Sluijs I, Spijkerman AMW, van der Schouw YT. Dietary phylloquinone and menaquinones intakes and risk of Type 2 diabetes. Diabetes Care 33, 1699-1705 (2010).
47. Yoshida M, Jacques PF, Meigs JB et al. Effect of vitamin K supplementation on insulin resistance in older men and women. Diabetes Care 31, 2092-2096 (2008).
48. Vestergaard P. Discrepancies in bone mineral density and fracture risk in patients with Type 1 and Type 2 diabetes - a meta-analysis. Osteoporos. Int. 18, 427-444 (2007).
49. Merlotti D, Gennari L, Dotta F, Lauro D, Nuti R. Mechanisms of impaired bone strength in Type 1 and 2 diabetes. Nutr. Metab. Cardiovasc. Dis. 20(9), 683-690 (2010).
50. Ferron M, Wei J, Yoshizawa T et al. Insulin signaling in osteoblasts integrates bone remodelling and energy metabolism. Cell 142, 296-308 (2010). Study from the Karsenty laboratory documenting that insulin receptor signaling in osteoblasts modulates whole-body glucose metabolism in mice via decarboxylation of osteocalcin.
51. Fulzele K, Riddle RC, DiGirolamo DJ et al. Insulin receptor signaling in osteoblasts regulates postnatal bone acquisition and body composition. Cell 142, 309-319 (2010). Study from the Clemens laboratory demonstrating how insulin receptor action in osteoblasts regulates circulating undercarboxlyated osteocalcin levels and insulin resistance in mice.
52. Rosen CJ, Motyl KJ. No bones about it: insulin modulates skeletal remodelling. Cell 142, 198-200 (2010).
53. Shoback D. Update in osteoporosis and metabolic bone disorders. J. Clin. Endocrinol. Metab. 92, 747-753 (2007).
54. Khosla S, Amin S, Orwoll E. Osteoporosis in men. Endocr. Rev. 29, 441-464 (2008).
55. Lewiecki EM. Treatment of osteoporosis with denosumab. Maturitas 66, 182-186 (2010).